Your browser doesn't support javascript.
Rapidly Increasing Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence and Limited Clinical Disease in 3 Malian Communities: A Prospective Cohort Study.
Sagara, Issaka; Woodford, John; Kone, Mamady; Assadou, Mahamadoun Hamady; Katile, Abdoulaye; Attaher, Oumar; Zeguime, Amatigue; Doucoure, M'Bouye; Higbee, Emily; Lane, Jacquelyn; Mohan, Rathy; Doritchamou, Justin; Zaidi, Irfan; Esposito, Dominic; Kwan, Jennifer; Sadtler, Kaitlyn; Dicko, Alassane; Duffy, Patrick E.
  • Sagara I; Malaria Research and Training Center/University of Sciences, Techniques and Techniques of Bamako, Bamako, Mali.
  • Woodford J; Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Maryland, Bethesda, USA.
  • Kone M; Malaria Research and Training Center/University of Sciences, Techniques and Techniques of Bamako, Bamako, Mali.
  • Assadou MH; Malaria Research and Training Center/University of Sciences, Techniques and Techniques of Bamako, Bamako, Mali.
  • Katile A; Malaria Research and Training Center/University of Sciences, Techniques and Techniques of Bamako, Bamako, Mali.
  • Attaher O; Malaria Research and Training Center/University of Sciences, Techniques and Techniques of Bamako, Bamako, Mali.
  • Zeguime A; Malaria Research and Training Center/University of Sciences, Techniques and Techniques of Bamako, Bamako, Mali.
  • Doucoure M; Malaria Research and Training Center/University of Sciences, Techniques and Techniques of Bamako, Bamako, Mali.
  • Higbee E; Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Maryland, Bethesda, USA.
  • Lane J; Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Maryland, Bethesda, USA.
  • Mohan R; Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Maryland, Bethesda, USA.
  • Doritchamou J; Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Maryland, Bethesda, USA.
  • Zaidi I; Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Maryland, Bethesda, USA.
  • Esposito D; Frederick National Laboratory for Cancer Research, National Institutes of Health, Maryland, Frederick, USA.
  • Kwan J; Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Maryland, Bethesda, USA.
  • Sadtler K; National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Maryland, Bethesda, USA.
  • Dicko A; Malaria Research and Training Center/University of Sciences, Techniques and Techniques of Bamako, Bamako, Mali.
  • Duffy PE; Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Maryland, Bethesda, USA.
Clin Infect Dis ; 74(6): 1030-1038, 2022 03 23.
Article in English | MEDLINE | ID: covidwho-1701582
ABSTRACT

BACKGROUND:

The extent of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exposure and transmission in Mali and the surrounding region is not well understood. We aimed to estimate the cumulative incidence of SARS-CoV-2 in 3 communities and understand factors associated with infection.

METHODS:

Between July 2020 and January 2021, we collected blood samples and demographic, social, medical, and self-reported symptoms information from residents aged 6 months and older over 2 study visits. SARS-CoV-2 antibodies were measured using a highly specific 2-antigen enzyme-linked immunosorbent assay optimized for use in Mali. We calculated cumulative adjusted seroprevalence for each community and evaluated factors associated with serostatus at each visit by univariate and multivariate analysis.

RESULTS:

Overall, 94.8% (2533/2672) of participants completed both study visits. A total of 31.3% (837/2672) were aged <10 years, 27.6% (737/2672) were aged 10-17 years, and 41.1% (1098/2572) were aged ≥18 years. The cumulative SARS-CoV-2 exposure rate was 58.5% (95% confidence interval, 47.5-69.4). This varied between sites and was 73.4% in the urban community of Sotuba, 53.2% in the rural town of Bancoumana, and 37.1% in the rural village of Donéguébougou. Study site and increased age were associated with serostatus at both study visits. There was minimal difference in reported symptoms based on serostatus.

CONCLUSIONS:

The true extent of SARS-CoV-2 exposure in Mali is greater than previously reported and may now approach hypothetical "herd immunity" in urban areas. The epidemiology of the pandemic in the region may be primarily subclinical and within background illness rates.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Language: English Journal: Clin Infect Dis Journal subject: Communicable Diseases Year: 2022 Document Type: Article Affiliation country: Cid

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Language: English Journal: Clin Infect Dis Journal subject: Communicable Diseases Year: 2022 Document Type: Article Affiliation country: Cid